Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials
Background: Acute migraine is the most common disabling chronic neurological disorder in the world. There are a huge proportion of unmet needs in treatment efficacy and satisfaction with currently available drugs and hence need for newer agents. One such FDA-approved drug is 5-HT1F Agonist lasmidita...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Eldaghayes Publisher
2022-09-01
|
| シリーズ: | National Journal of Physiology, Pharmacy and Pharmacology |
| 主題: | |
| オンライン･アクセス: | http://www.ejmanager.com/fulltextpdf.php?mno=141058 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|